Lexington Medical, a leader in minimally invasive surgical stapling solutions, announced a strategic investment by Ampersand Capital Partners. This partnership emphasizes Ampersand’s confidence in Lexington’s potential to transform surgical stapling standards and positions the company for accelerated growth in product innovation, smart manufacturing, and global market expansion.
Launched in 2013 and based in Bedford, MA, Lexington Medical designs and manufactures high-performance endoscopic stapling devices, which are made in the USA and used in a wide range of surgical procedures.
With international offices in Switzerland, Australia, Germany, and the UK, and a team of about 150 employees, Lexington has built a patented portfolio of over 40 SKUs trusted by surgeons in more than 35 countries. And its flagship AEON and AEON Powered Stapling platforms are known as the most advanced stapling platforms available, featuring proprietary technologies that deliver superior clinical outcomes.
This deal comes at a pivotal time as Lexington Medical expands its world-class team to meet the growing demand for its stapling solutions.
KEY QUOTES:
“The investment from Ampersand is a testament to Lexington’s impressive growth and strategic vision. This investment will expedite our innovation pipeline, expand our global reach, and create new opportunities for talented professionals to join us in shaping the future of surgical care, all while maintaining our commitment to best-in-class quality control and US manufacturing.”
– Leon Amariglio, Founder and CEO of Lexington Medical
“Lexington is an impressive company with a strong culture of innovation, exceptional leadership, and a commitment to quality and performance that is unmatched. We are excited to partner with Leon and his team to further strengthen their position in surgical stapling.”
– Trevor Wahlbrink, General Partner at Ampersand
